Introduction
Living with schizophrenia or schizoaffective disorder often requires long-term treatment to help manage symptoms, reduce the risk of relapse, and support daily functioning. For many patients, staying on a consistent medication schedule can be challenging, making long-acting injectable therapies an important treatment option.
Invega Sustenna is a prescription long-acting injectable antipsychotic approved to treat schizophrenia and schizoaffective disorder in adults. After an initial two-dose regimen, the medication is administered once monthly by a healthcare professional, providing continuous delivery over several weeks. By helping regulate dopamine and serotonin activity in the brain, Invega Sustenna may help reduce hallucinations, delusions, disorganized thinking, and mood-related symptoms.
As a specialty injectable medication, Invega Sustenna can be expensive without adequate insurance coverage or financial assistance. Many patients searching for the Invega Sustenna patient assistance program are looking for ways to reduce out-of-pocket treatment costs while maintaining consistent access to therapy.
Prescription Hope offers qualified patients access to affordable brand-name medications such as Invega Sustenna.
What Is the Invega Sustenna Patient Assistance Program?
Understanding Invega Sustenna Prescription Assistance
Manufacturers of brand-name medications understand that not all of their medications are affordable at retail prices. To help Americans get access to their needed brand-name medications, manufacturers often offer patient assistance programs.
With patient assistance programs, qualified patients access affordable brand-name medications at low to no cost.
However, these programs have been known to include difficult and confusing application processes. Many patients who attempt to apply on their own report bureaucratic red tape and a complex landscape that leaves them feeling frustrated. Some even give up, either trying to find another way to save or leaving their prescription unfilled altogether.
Prescription Hope provides a solution.
How Expert Advocates Help Make Invega Sustenna More Affordable
Personalized Medication Assistance
Prescription Hope is a patient support service that provides medication advocate support to those looking to apply for patient assistance programs.
Our team of patient advocates helps with Invega Sustenna enrollment assistance by managing form completion, document and signature collection, coordination with healthcare providers and manufacturers, and more.
Ongoing Patient Support
And while Americans appreciate our team of patient advocates’ support and advocacy throughout the application process, we offer even more.
Prescription Hope provides long-term medication assistance and helps ensure treatment continuity. We handle administrative tasks such as document and form updates, program monitoring, issue resolution, yearly renewals, and even refill scheduling.
Invega Sustenna Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: GoodRX
Navigating Long-Acting Antipsychotic Costs
If you’re looking for schizophrenia medication affordability and cannot currently afford Invega Sustenna out of pocket, then Prescription Hope may be able to help.
Qualified patients pay only $70.00 per month, per medication. This means we never tack on hidden fees, variable pricing, add-ons, or medication costs.
And if we can’t help, you don’t pay!
Invega Sustenna Patient Assistance Eligibility
General Eligibility Requirements
Because prescription assistance requirements are specific to each program, such as the Invega Sustenna Patient Assistance Program, enrolling with Prescription Hope gives you the ability to learn more about the specific program’s requirements.
However, each program uses several general categories to determine criteria. Those include:
U.S. Residency: All qualified patients must be legal U.S. residents.
Prescription: All qualified patients must have a valid prescription for the medication they aim to apply for.
Insurance: Every program maintains a requirement regarding insurance coverage status. Each program differs in specific levels of coverage allowed for qualification.
Income: Each program may differ in the income threshold used for program qualification.
Simple Enrollment With Expert Support
Getting Started With Enrollment
A patient ready to enroll in Invega Sustenna assistance need look no further than Prescription Hope. To get started with medication assistance enrollment and prescription support services, it only takes 6 steps:
- Submit Information: Our online form can be finished in a matter of minutes.
- Advocate Contact: Once we get your finished form, a patient advocate will reach out within 1-2 business days.
- Document Collection: After a quick prequalification, our team of patient advocates will collect all necessary documentation.
- Provider Coordination: Our team also communicates with your healthcare provider to secure needed signatures.
- Program Submission: Once we have everything in order, our team submits your application packet and continues to coordinate with the manufacturer.
- Medication Delivery: After approval, patients typically receive their medication within 2 weeks. All medications ship directly from the manufacturer to your home or doctor’s office.
Understanding Invega Sustenna
How Invega Sustenna Works
Invega Sustenna contains paliperidone palmitate, a long-acting form of the antipsychotic medication paliperidone. After being injected into a muscle, the medication is gradually released into the bloodstream over several weeks, providing continuous treatment between monthly injections.
Paliperidone works by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain. By helping balance the activity of these neurotransmitters, Invega Sustenna may reduce symptoms such as hallucinations, delusions, disorganized thinking, and mood disturbances associated with schizophrenia and schizoaffective disorder.
The long-acting injectable formulation helps maintain consistent medication levels and may improve treatment adherence for patients who have difficulty taking a daily oral medication.
What Conditions Does Invega Sustenna Treat?
Invega Sustenna is FDA-approved for the treatment of schizophrenia in adults and schizoaffective disorder in adults.
For schizoaffective disorder, Invega Sustenna may be used either as monotherapy or together with mood stabilizers or antidepressants when appropriate.
Following an initial two-dose initiation regimen, the medication is administered once monthly by a healthcare professional to provide ongoing symptom control and help reduce the risk of relapse.
Benefits of Treatment
Invega Sustenna provides long-acting treatment for schizophrenia and schizoaffective disorder by delivering medication continuously over several weeks after each monthly injection.
Potential benefits include reducing hallucinations and delusions, improving thinking and daily functioning, helping stabilize mood in patients with schizoaffective disorder, reducing the risk of relapse, improving medication adherence through once-monthly dosing, and eliminating the need for daily oral antipsychotic medication for many patients after treatment initiation.
Treatment responses vary among individuals, and ongoing therapy is often necessary to maintain symptom control. Healthcare providers routinely monitor treatment response and overall health throughout long-term therapy.
Important Safety Information and Side Effects
Invega Sustenna carries an FDA Boxed Warning.
The Boxed Warning states that elderly patients with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death. Invega Sustenna is not approved for the treatment of patients with dementia-related psychosis.
The most commonly reported side effects include injection site reactions, weight gain, sleepiness (somnolence), restlessness (akathisia), headache, dizziness, tremor, increased heart rate (tachycardia), constipation, dry mouth, elevated prolactin levels, muscle stiffness (extrapyramidal symptoms), and anxiety. Patients should contact their healthcare provider if side effects become severe or persistent.
Elderly patients with dementia-related psychosis who receive antipsychotic medications also have an increased risk of cerebrovascular adverse events, including stroke and transient ischemic attack (TIA).
A rare but potentially life-threatening condition known as neuroleptic malignant syndrome (NMS) has occurred during treatment. Patients should seek immediate medical attention if they develop high fever, severe muscle stiffness, confusion, sweating, or a rapid heartbeat.
Long-term use may lead to tardive dyskinesia, a condition involving involuntary movements of the face, tongue, mouth, or extremities that may become permanent.
Paliperidone may cause QT interval prolongation, increasing the risk of serious heart rhythm abnormalities. Patients with existing heart rhythm disorders or those taking other medications that prolong the QT interval may require additional monitoring.
Treatment may cause metabolic changes, including hyperglycemia, diabetes mellitus, weight gain, increased cholesterol, and elevated triglycerides. Routine monitoring of weight, blood glucose, and lipid levels is recommended.
Invega Sustenna may cause orthostatic hypotension and syncope, leading to dizziness, low blood pressure upon standing, or fainting, which may increase the risk of falls.
Cases of leukopenia, neutropenia, and agranulocytosis have been reported. Patients with a history of clinically significant low white blood cell counts may require periodic complete blood count monitoring.
Paliperidone commonly causes hyperprolactinemia, which may result in missed menstrual periods, breast enlargement, milk production unrelated to pregnancy, sexual dysfunction, and reduced fertility.
Because sleepiness, low blood pressure, and motor instability may occur, treatment may increase the risk of falls, particularly in older adults or individuals with other risk factors.
Exposure during the third trimester of pregnancy may cause extrapyramidal symptoms or withdrawal symptoms in newborns. Patients who are pregnant, planning to become pregnant, or breastfeeding should discuss treatment with their healthcare provider before receiving Invega Sustenna.
Patients should inform their healthcare provider about all medications they take. Important interactions include strong CYP3A4/P-glycoprotein (P-gp) inducers such as carbamazepine, rifampin, and St. John’s wort; medications that prolong the QT interval; other central nervous system depressants; and blood pressure-lowering medications. Alcohol may increase certain nervous system side effects.
Invega Sustenna is administered as an intramuscular injection by a healthcare professional into the deltoid or gluteal muscle. Treatment begins with a two-dose initiation regimen during the first week, followed by once-monthly maintenance injections. Once tolerability to oral paliperidone or risperidone has been established, routine oral supplementation is not required. Dosage adjustments may be necessary for patients with reduced kidney function, and injections should be received on schedule to maintain therapeutic drug levels.
Healthcare providers typically monitor extrapyramidal symptoms, tardive dyskinesia, weight, blood glucose, lipid levels, prolactin levels, blood pressure, complete blood counts when clinically indicated, and the QT interval in patients with cardiac risk factors throughout treatment.
Access to Multiple Medications
Support Beyond Invega Sustenna
Need access to multiple medication assistance programs?
Prescription Hope’s list of hundreds of accessible brand-name medications means we may be able to help you qualify for some, if not all, of your medications.
And our low service fee remains the same: $70.00 per month, per medication.
Why Choose Prescription Hope for Invega Sustenna Assistance
Patient-Focused Medication Support
Prescription Hope has provided advocacy and support for Americans across the nation for the past two decades. With a team of medication access specialists, our patients can rest easy knowing that we take care of the process from start to finish.
Simplified Access to Specialty Medications
While other treatment affordability solutions may provide a small percentage off total medication costs, Prescription Hope’s simple service fee not only covers our assistance with the entire application and enrollment process, but also takes care of your medication costs.
That means you get access to your medication for $70.00 per month, per medication.
Ongoing Prescription Assistance
For those who are looking for schizophrenia and schizoaffective disorder treatment support, Prescription Hope can help. We not only provide assistance through the patient assistance program application process, but also help take care of administrative tasks related to ongoing enrollment.
If you need Invega Sustenna cost assistance and are interested in enrolling in the Invega Sustenna Patient Assistance Program, then be sure to submit an enrollment form with Prescription Hope today!